keyword
MENU ▼
Read by QxMD icon Read
search

protease inhibitors with lipoprotein in hiv

keyword
https://www.readbyqxmd.com/read/27740537/hyperlipidaemia-in-hiv-infected-patients-on-lopinavir-ritonavir-monotherapy-in-resource-limited-settings
#1
Mitch M Matoga, Mina C Hosseinipour, Evgenia Aga, Heather J Ribaudo, Nagalingeswaran Kumarasamy, John Bartlett, Michael D Hughes
BACKGROUND: Cardiovascular disease (CVD) is an emerging concern for HIV-infected patients. Hyperlipidemia is a risk factor for CVD and a complication of protease-inhibitor-based antiretroviral therapy, but little is known about its incidence and risk factors in treated patients in resource-limited settings (RLS). METHODS: We conducted a secondary analysis of ACTG A5230 trial in which HIV-infected adults from India, Malawi, Tanzania, Thailand and South Africa, with virologic relapse on first line therapy were initiated on lopinavir/ritonavir (LPV/r) monotherapy...
October 14, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27661466/changes-in-plasma-levels-of-oxidized-lipoproteins-and-lipoprotein-subfractions-with-atazanavir-raltegravir-darunavir-based-initial-antiviral-therapy-and-associations-with-common-carotid-artery-intima-media-thickness-actg-5260s
#2
Theodoros Kelesidis, Thuy Tien T Tran, Todd T Brown, Carlee Moser, Heather J Ribaudo, Michael P Dube, Otto O Yang, Grace A McComsey, James H Stein, Judith S Currier
BACKGROUND: The role of oxidized lipoproteins (high-density [HDLox] and low-density [LDLox]) and total lipoprotein particle (Lp) number and size in HIV-related cardiovascular disease (CVD) is unclear. The goal of this study was to evaluate changes of these biomarkers and their associations with rate of carotid intima media thickness progression over 3 years (ΔCIMT) in chronic HIV infection. METHODS: Prospective study of 234 HIV-infected antiretroviral treatment naïve participants without CVD who were randomized to receive tenofovir-emtricitabine plus atazanavir/ritonavir, darunavir/ ritonavir, or raltegravir (RAL) and achieved plasma HIV-1 RNA <50 copies/ml by week 24 and thereafter...
September 23, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27603288/oxidized-lipoproteins-are-associated-with-markers-of-inflammation-and-immune-activation-in-hiv-1-infection
#3
Theodoros Kelesidis, Nicholas Jackson, Grace A McComsey, Xiaoyan Wang, David Elashoff, Michael P Dube, Todd T Brown, Otto O Yang, James H Stein, Judith S Currier
OBJECTIVE: The pathogenesis of immune dysfunction in chronic HIV-1 infection is unclear, and a potential role for oxidized lipids has been suggested. We hypothesize that both oxidized HDL and LDL (HDLox and LDLox) contribute to HIV-1-related immune dysfunction. STUDY: In the AIDS Clinical Trials Group A5260, 234 HIV-infected antiretroviral therapy (ART)-naive participants were randomized to receive tenofovir-emtricitabine and protease inhibitors or raltegravir and had HIV-1 RNA less than 50 copies/ml by week 24 and thereafter...
November 13, 2016: AIDS
https://www.readbyqxmd.com/read/27409415/severe-dyslipidemia-and-immune-activation-in-hiv-patients-with-dysglycemia
#4
Changzhong Jin, Shujing Ji, Tiansheng Xie, Stefan Höxtermann, Wolfgang Fuchs, Xiangyun Lu, Haibo Wu, Linfang Cheng, Adriane Skaletz-Rorowski, Norbert H Brockmeyer, Nanping Wu
BACKGROUND AND OBJECTIVE: Diabetes mellitus (DM) is common in human immunodeficiency virus (HIV)-infected patients. However, the relationship between dysglycemia, lipid metabolism, and immune activation in HIV patients is poorly understood. METHODS: We retrospectively analyzed the clinical data of 180 HIV patients, including 153 patients undergoing highly active antiretroviral therapy (HAART) and 27 HAART-naive patients. DM was defined as fasting serum glucose levels ≥126 mg/dl, and impaired fasting glucose (IFG) was defined as serum glucose levels of 101-125 mg/dl at two different time points...
September 2016: HIV Clinical Trials
https://www.readbyqxmd.com/read/27304841/effects-of-pitavastatin-on-lipid-profiles-in-hiv-infected-patients-with-dyslipidemia-and-receiving-atazanavir-ritonavir-a-randomized-double-blind-crossover-study
#5
Asita Wongprikorn, Chonlaphat Sukasem, Apichaya Puangpetch, Pawin Numthavej, Ammarin Thakkinstian, Sasisopin Kiertiburanakul
BACKGROUND: Dyslipidemia as a risk factor of cardiovascular disease is common especially in HIV-infected patients who are using protease inhibitors (PIs) including atazanavir. Pitavastatin has less drug-drug interactions and demonstrable efficacy in decreasing lipid levels in non HIV-infected individuals. MATERIALS AND METHODS: This study was a randomized, double-blind, crossover study comparing the safety and efficacy of pitavastatin vs placebo in HIV-infected patients with dyslipidemia and receiving atazanavir/ritonavir (ATV/r)...
2016: PloS One
https://www.readbyqxmd.com/read/27270208/efavirenz-and-ritonavir-boosted-lopinavir-use-exhibited-elevated-markers-of-atherosclerosis-across-age-groups-in-people-living-with-hiv-in-ethiopia
#6
Rudolph L Gleason, Alexander W Caulk, Daniel Seifu, Julia C Rosebush, Alyssa M Shapiro, Matthew H Schwartz, Allison Ross Eckard, Wondwossen Amogne, Workeabeba Abebe
BACKGROUND: HIV patients on highly-active antiretroviral therapy (HAART) have shown elevated incidence of dyslipidemia, lipodystrophy, and markers of cardiovascular disease. Evidence is beginning to emerge that implicates efavirenz (EFV) as a potential mediator of early on-set cardiovascular disease. METHODS: Pediatric and adult HIV-infected HAART-naïve, EFV-treated, nevirapine (NVP)-treated, and ritonavir-boosted lopinavir (LPV/r)-treated subjects were recruited from Black Lion Hospital in Addis Ababa, Ethiopia...
May 21, 2016: Journal of Biomechanics
https://www.readbyqxmd.com/read/27188902/the-actn3-r577x-polymorphism-affects-the-lipid-profile-and-the-prognosis-of-nutritional-intervention-in-hiv-positive-patients
#7
Laura C R Aranalde, Bruna S Pederzoli, Thais Marten, Flavio C Barros, Rossana P Basso, Jussara M Silveira, Sandra C Valle, Simone Pieniz, Ronaldo C Araujo, Edgar J Paredes-Gamero, Ines Schadock, Augusto Schneider, Carlos C Barros
The hypothesis of the present study is that the polymorphisms in the APOC3, CEPT, ACE, and ACTN3 genes can affect the outcome of nutritional intervention and the plasma lipid profile of HIV+ patients. To test the hypothesis, genetic material was collected from buccal cells, and serum was collected for biochemical analysis. Sixty-five patients were analyzed. The incorporation of protease inhibitor (PI) was more frequent in women (77% vs 33% in men). Nutritional intervention improved anthropometric parameters independent of the genotype...
June 2016: Nutrition Research
https://www.readbyqxmd.com/read/26987376/rosuvastatin-vs-protease-inhibitor-switching-for-hypercholesterolaemia-a-randomized-trial
#8
F J Lee, P Monteiro, D Baker, M Bloch, N Roth, R Finlayson, R Moore, J Hoy, E Martinez, A Carr
OBJECTIVES: The aim of the study was to compare the efficacy and safety of rosuvastatin initiation with those of switching of ritonavir-boosted protease inhibitors (PI/rs) in HIV-1-infected adults with hypercholesterolaemia and increased cardiovascular risk scores. METHODS: In this open-label, multicentre study, HIV-1-infected adults on PI/r-based therapy with viral load < 50 HIV-1 RNA copies/mL, fasting total cholesterol ≥ 5.5 mmol/L (both for ≥ 6 months) and elevated cardiovascular risk (Framingham score ≥ 8% or diabetes or family history), and not on lipid-lowering therapy, were randomized to open-label rosuvastatin 10 mg/day or to PI/r switching, both with standardized diet/exercise advice...
September 2016: HIV Medicine
https://www.readbyqxmd.com/read/26858314/lipid-changes-in-virologically-suppressed-hiv-infected-patients-switching-from-any-antiretroviral-therapy-to-the-emtricitabine-rilpivirine-tenofovir-single-tablet-gesida-study-8114
#9
Rosario Palacios, Marisa Mayorga, Isabel A Pérez-Hernández, Antonio Rivero, Alfonso Del Arco, Fernando Lozano, Jesús Santos
We carried out a retrospective, multicenter study of a cohort of 298 asymptomatic HIV-infected patients who switched from a regimen based on 2 nucleoside reverse transcriptase inhibitors + protease inhibitor (PI)/nonnucleoside reverse transcriptase inhibitor or ritonavir-boosted PI monotherapy to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) to analyze lipid changes. At 24 weeks, 284 (95.3%) patients were still taking the same regimen, maintaining similar CD4 counts as at baseline (651 versus 672 cells/mm(3), P = ...
May 2016: Journal of the International Association of Providers of AIDS Care
https://www.readbyqxmd.com/read/26648662/plasma-nitration-of-high-density-and-low-density-lipoproteins-in-chronic-kidney-disease-patients-receiving-kidney-transplants
#10
Ahmed Bakillah, Fasika Tedla, Isabelle Ayoub, Devon John, Allen J Norin, M Mahmood Hussain, Clinton Brown
BACKGROUND: Functional abnormalities of high-density lipoprotein (HDL) could contribute to cardiovascular disease in chronic kidney disease patients. We measured a validated marker of HDL dysfunction, nitrated apolipoprotein A-I, in kidney transplant recipients to test the hypothesis that a functioning kidney transplant reduces serum nitrated apoA-I concentrations. METHODS: Concentrations of nitrated apoA-I and apoB were measured using indirect sandwich ELISA assays on sera collected from each transplant subject before transplantation and at 1, 3, and 12 months after transplantation...
2015: Mediators of Inflammation
https://www.readbyqxmd.com/read/26396442/metabolic-abnormalities-in-human-immunodeficiency-virus-patients-with-protease-inhibitor-based-therapy
#11
Tumnyak Ete, Salam Ranabir, Narmada Thongam, Biplab Ningthoujam, Narendra Rajkumar, Bhimo Thongam
CONTEXT: Several studies have reported metabolic abnormalities in patients taking protease inhibitor (PI) based therapy from several parts of the world. But there is no prospective study in India after switching from PI sparing regimen to PI based regimen. AIMS: To assess whether North-East Indian Human Immunodeficiency Virus (HIV) patients also develop similar metabolic abnormalities to PI. SETTINGS AND DESIGN: This prospective study was conducted in Anti-retroviral therapy (ART) Centre of Excellence, at a tertiary care Medical Institute...
July 2014: Indian Journal of Sexually Transmitted Diseases
https://www.readbyqxmd.com/read/26372383/a-prospective-randomized-clinical-trial-of-antiretroviral-therapies-on-carotid-wall-thickness
#12
RANDOMIZED CONTROLLED TRIAL
James H Stein, Heather J Ribaudo, Howard N Hodis, Todd T Brown, Thuy Tien T Tran, Mingzhu Yan, Elizabeth Lauer Brodell, Theodore Kelesidis, Grace A McComsey, Michael P Dube, Robert L Murphy, Judith S Currier
OBJECTIVE: This article compares the effects of initiating three contemporary antiretroviral therapy (ART) regimens on progression of carotid artery intima-media thickness (IMT) over 3 years. DESIGN: Randomized clinical trial. SETTING: Multicenter (26 institutions). PATIENTS: ART-naive HIV-infected individuals (n = 328) without known cardiovascular disease or diabetes mellitus. INTERVENTION: Random assignment to tenofovir/emtricitabine along with atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or raltegravir (RAL)...
September 10, 2015: AIDS
https://www.readbyqxmd.com/read/26343868/hiv-infection-induces-structural-and-functional-changes-in-high-density-lipoproteins
#13
Marc O Siegel, Alison G Borkowska, Larisa Dubrovsky, Mary Roth, Ruth Welti, Afsoon D Roberts, David M Parenti, Gary L Simon, Dmitri Sviridov, Samuel Simmens, Michael Bukrinsky, Michael L Fitzgerald
BACKGROUND AND AIMS: Coronary artery disease is a growing clinical problem in HIV-infected subjects. The increased risk of coronary events in this population has been linked to low levels of HDL, but the effects of HIV infection and anti-retroviral treatment (ART) on HDL structure and function remain unknown. Here, we aimed to determine the composition and function of HDL particles isolated from ART-naive and ART-positive HIV-infected patients. METHODS AND RESULTS: Proteomic profiling revealed decreased levels of paraoxonase (PON) 1 and PON 3 in HDL from HIV patients relative to HDL from uninfected controls (p < 0...
November 2015: Atherosclerosis
https://www.readbyqxmd.com/read/26232000/efficacy-and-safety-in-clinical-practice-of-a-rilpivirine-tenofovir-and-emtricitabine-single-tablet-regimen-in-virologically-suppressed-hiv-positive-patients-on-stable-antiretroviral-therapy
#14
Nicola Gianotti, Andrea Poli, Silvia Nozza, Vincenzo Spagnuolo, Giuseppe Tambussi, Simona Bossolasco, Paola Cinque, Myriam Maillard, Massimo Cernuschi, Laura Galli, Adriano Lazzarin, Antonella Castagna
INTRODUCTION: Switching to a rilpivirine, tenofovir and emtricitabine (RTE) single-tablet regimen (STR) has been evaluated in a limited number of virologically suppressed patients. The aim of this study was to describe clinical outcomes in HIV-positive patients switched from a suppressive antiretroviral regimen to RTE STR in routine clinical practice. METHODS: In this retrospective study of antiretroviral-treated patients with <50 copies of HIV RNA/mL switched to RTE STR, virological failure (VF) was defined as two consecutive measurements of ≥50 copies/mL or a single measurement of ≥50 copies/mL followed by any change in treatment...
2015: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/25989829/switch-to-etravirine-for-hiv-positive-patients-receiving-statin-treatment-a-prospective-study
#15
MULTICENTER STUDY
Laura Ciaffi, Matthias Cavassini, Daniel Genne, Cecile Delhumeau, Rachel Spycher Elbes, Andrew Hill, Gilles Wandeler, Jan Fehr, Marcel Stoeckle, Patrick Schmid, Bernard Hirschel, Fabrizio Montecucco, Alexandra Calmy
BACKGROUND: Lifestyle changes and statins are the cornerstones in management of dyslipidaemia in patients with HIV infection. Replacement of an antiretroviral therapy (ART) component is a proposed therapeutic strategy to reduce cardiovascular risk. In dyslipidaemic patients with HIV infection, we assessed the efficacy of replacing boosted protease inhibitor (bPI) or efavirenz (EFV) by etravirine (ETR) as an alternative to statin therapy. MATERIALS AND METHODS: A prospective, open-label, multicentre, 12-week study of patients with HIV infection on ART including bPI or EFV, and statin treatment...
July 2015: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/25882821/an-updated-prediction-model-of-the-global-risk-of-cardiovascular-disease-in-hiv-positive-persons-the-data-collection-on-adverse-effects-of-anti-hiv-drugs-d-a-d-study
#16
MULTICENTER STUDY
Nina Friis-Møller, Lene Ryom, Colette Smith, Rainer Weber, Peter Reiss, F Dabis, Stephane De Wit, Antonella D'Arminio Monforte, Ole Kirk, Eric Fontas, Caroline Sabin, Andrew Phillips, Jens Lundgren, Matthew Law
BACKGROUND: With the aging of the population living with HIV, the absolute risk of cardiovascular disease (CVD) is increasing. There is a need to further facilitate the identification of persons at elevated risk in routine practice. METHODS AND RESULTS: Prospective information was collected on 32,663 HIV-positive persons from 20 countries in Europe and Australia, who were free of CVD at entry into the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study...
January 2016: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/25767256/comparison-of-the-metabolic-effects-of-ritonavir-boosted-darunavir-or-atazanavir-versus-raltegravir-and-the-impact-of-ritonavir-plasma-exposure-actg-5257
#17
RANDOMIZED CONTROLLED TRIAL
Ighovwerha Ofotokun, Lumine H Na, Raphael J Landovitz, Heather J Ribaudo, Grace A McComsey, Catherine Godfrey, Francesca Aweeka, Susan E Cohn, Manish Sagar, Daniel R Kuritzkes, Todd T Brown, Kristine B Patterson, Michael F Para, Randi Y Leavitt, Angelina Villasis-Keever, Bryan P Baugh, Jeffrey L Lennox, Judith S Currier
BACKGROUND: Metabolic effects following combination antiretroviral therapy (cART) vary by regimen type. Changes in metabolic effects were assessed following cART in the AIDS Clinical Trials Group (ACTG) A5257 study, and correlated with plasma ritonavir trough concentrations (C24). METHODS: Treatment-naive adult subjects were randomized to ritonavir-boosted atazanavir or darunavir, or raltegravir-based cART. Changes in lipids and other metabolic outcomes over time were estimated...
June 15, 2015: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/25686680/statin-therapy-decreases-n-terminal-pro-b-type-natriuretic-peptide-in-hiv-randomized-placebo-controlled-trial
#18
RANDOMIZED CONTROLLED TRIAL
Sahera Dirajlal-Fargo, Bruce Kinley, Ying Jiang, Chris T Longenecker, Corrilynn O Hileman, Sara Debanne, Grace A McComsey
OBJECTIVE: HIV-infected participants are at a higher risk for cardiovascular disease (CVD). N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a significant predictor of CVD in the general population and is associated with mortality in HIV. DESIGN AND METHODS: The 96-week Stopping Atherosclerosis and Treating Unhealthy Bone with Rosuvastatin in HIV (SATURN-HIV) trial randomized 147 patients on stable antiretroviral therapy with low-density lipoprotein-cholesterol level lower than 130 mg/dl and without overt heart failure to 10 mg daily rosuvastatin or placebo...
January 28, 2015: AIDS
https://www.readbyqxmd.com/read/25472015/lipid-metabolism-and-lipodystrophy-in-hiv-1-infected-patients-the-role-played-by-nonnucleoside-reverse-transcriptase-inhibitors
#19
Michael Sension, Henri Deckx
Dyslipidemia and lipodystrophy represent significant healthcare concerns in HIV-infected patients due to their association with diabetes mellitus and increased cardiovascular disease risk. Since the lipid effects of the nonnucleoside reverse transcriptase inhibitors are not well characterized, we systematically summarized the effects of nonnucleoside reverse transcriptase inhibitor treatment on dyslipidemia and lipodystrophy in HIV-1 infection. As with other classes of antiretroviral agents, the nonnucleoside reverse transcriptase inhibitors are associated with lipid changes, although individual agents exhibit differing effects on lipid profiles...
January 2015: AIDS Reviews
https://www.readbyqxmd.com/read/25389256/differential-body-composition-effects-of-protease-inhibitors-recommended-for-initial-treatment-of-hiv-infection-a-randomized-clinical-trial
#20
RANDOMIZED CONTROLLED TRIAL
Esteban Martinez, Ana Gonzalez-Cordon, Elena Ferrer, Pere Domingo, Eugenia Negredo, Felix Gutierrez, Joaquin Portilla, Adrià Curran, Daniel Podzamczer, Esteban Ribera, Javier Murillas, Jose I Bernardino, Ignacio Santos, Jose A Carton, Joaquim Peraire, Judit Pich, Ramon Deulofeu, Ignacio Perez, Jose M Gatell
BACKGROUND: It is unclear whether metabolic or body composition effects differ between protease inhibitor-based regimens recommended for initial treatment of human immunodeficiency virus (HIV) infection. METHODS: ATADAR is a phase 4, open-label, multicenter, randomized clinical trial. Stable antiretroviral-naive HIV-infected adults were randomly assigned to atazanavir/ritonavir 300/100 mg or darunavir/ritonavir 800/100 mg in combination with tenofovir/emtricitabine daily...
March 1, 2015: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
keyword
keyword
105481
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"